Your Treatment Plan: Cornstarch and Metabolic Control
At a Glance
The primary treatment for Glycogen Storage Disease Type I (GSD I) is maintaining strict metabolic control using around-the-clock doses of uncooked cornstarch and completely avoiding fructose and galactose. This prevents dangerously low blood sugar and the buildup of harmful lactic acid.
The foundation of living with Glycogen Storage Disease Type I (GSD I) is metabolic control. This means keeping blood sugar levels steady and avoiding the “metabolic panic” that leads to the buildup of lactic acid and fats [1]. While GSD I is a lifelong condition, it is highly responsive to a specialized dietary plan that revolves around providing the body with a constant, slow-release source of energy [2].
Infant Feeding and Dietary Restrictions
For infants under 6 to 12 months, uncooked cornstarch cannot be used because their digestive systems do not yet produce enough pancreatic amylase to digest raw starch [3]. Giving an infant cornstarch too early can cause severe gastrointestinal distress, gas, and diarrhea, leading to poor metabolic control.
- Specialized Formulas: Infants require frequent feedings (every 2 to 3 hours, day and night) using specialized sucrose-, fructose-, and lactose-free formulas, such as specific soy-based formulas [1]. Standard infant formula and breast milk cannot be used because they contain high amounts of lactose, which breaks down into galactose.
The Role of Cornstarch
As children reach 6 to 12 months of age and their digestive system matures, uncooked cornstarch becomes the primary tool for management [4].
- Uncooked Cornstarch: This acts as a “time-release” source of glucose. Because it is slow to digest, it provides a steady trickle of sugar into the bloodstream over several hours [5].
- Preparation Warning: It must be mixed with cold or room-temperature water or a sugar-free liquid. Mixing it with warm or hot water will “cook” the starch, breaking it down too quickly and destroying its slow-release effect [4].
- Extended-Release Cornstarch and Adult Schedules: As patients grow, their bodies can hold onto glucose longer. Older children and adults may transition to specialized extended-release cornstarch, which can last up to 4 to 8 hours [6]. This allows for significantly longer sleep intervals and improves overall quality of life [4][7].
Dietary Restrictions: Avoiding “Toxic” Sugars
While it might seem counterintuitive for a person with low blood sugar to avoid certain sugars, children and adults with GSD I must strictly restrict fructose (fruit sugar) and galactose (found in dairy/lactose) [1].
- The Reason: In GSD I, the body can take these sugars in, but it cannot turn them into usable glucose. Instead, they get “trapped” in the liver and are converted directly into lactate and triglycerides, worsening the metabolic imbalance [1][8].
- Management: This means avoiding most fruits, table sugar (sucrose, which is half fructose), and dairy products [1].
- Essential Supplements: Because restricting dairy and fruits eliminates major sources of calcium, vitamin D, and other nutrients, you will work closely with your dietitian to incorporate prescribed sugar-free multivitamins and calcium/vitamin D supplements to protect bone health and prevent malnutrition [9].
The Hidden Risk: Dental Health
A major consequence of eating carbohydrates (cornstarch) around the clock is the risk of severe tooth decay. Your teeth are constantly exposed to carbs without the natural protective benefits of the calcium in dairy. Rigorous daily dental hygiene and frequent visits to a dentist familiar with GSD I are critical to protecting your oral health [10].
Optimizing Control with Technology
Continuous Glucose Monitors (CGMs) have revolutionized GSD I care [11]. These small sensors provide real-time sugar readings every few minutes.
- Early Warning: They allow patients to see a drop in blood sugar before it becomes an emergency [12].
- Trend Tracking: CGMs help the medical team see if a cornstarch dose is wearing off too early or if blood sugar is spiking too high (hyperglycemia) after a dose, allowing for precise adjustments [11].
When Surgery is Considered
For the vast majority of patients, dietary management is successful. However, a liver transplant may be considered as a last resort in specific, rare situations:
- Refractory Cases: If blood sugar and lactate levels cannot be controlled even with the strictest diet [13].
- Liver Lesions: If a patient develops adenomas (non-cancerous liver tumors) that show signs of becoming cancerous or are growing aggressively despite good metabolic control [14][15].
- GSD Ib Considerations: It is important to note that while a liver transplant corrects the blood sugar issues, it does not cure the immune system challenges (neutropenia) associated with GSD Ib [16].
Common questions in this guide
Why do people with GSD 1 need uncooked cornstarch?
Why can't infants under 6 months have cornstarch?
Why do I have to avoid fruit and dairy with GSD 1?
How should you mix cornstarch for GSD treatment?
Is a liver transplant a cure for GSD 1?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How will you determine our child's specific cornstarch dose and frequency, and how often will this need to be adjusted as they grow?
- 2.What are our specific targets for blood glucose and lactate levels to ensure our child is in 'good metabolic control'?
- 3.How can we best use Continuous Glucose Monitor (CGM) data to adjust our child's daytime and overnight feeding schedules?
- 4.What specialized infant formula should we use since breast milk and standard formulas contain lactose?
- 5.Can you provide a specific list of foods or ingredients containing fructose or galactose that we must avoid?
- 6.When can we consider transitioning to extended-release cornstarch to allow for longer periods of sleep?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (16)
- 1
Glucose-6 Phosphate, A Central Hub for Liver Carbohydrate Metabolism.
Rajas F, Gautier-Stein A, Mithieux G
Metabolites 2019; (9(12)) doi:10.3390/metabo9120282.
PMID: 31756997 - 2
Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control.
Dambska M, Labrador EB, Kuo CL, Weinstein DA
Pediatric diabetes 2017; (18(5)):327-331 doi:10.1111/pedi.12540.
PMID: 28568353 - 3
Pancrelipase as Adjunctive Therapy in Severe SCOT Deficiency: A Case of a Novel OXCT1 Gene Deletion.
Hamdeh MA, Jaber L, Abdullah J, et al.
JIMD reports 2025; (66(3)):e70024 doi:10.1002/jmd2.70024.
PMID: 40406160 - 4
Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type I.
Ross KM, Brown LM, Corrado MM, et al.
JIMD reports 2016; (26()):85-90 doi:10.1007/8904_2015_488.
PMID: 26303612 - 5
Investigation and management of the hepatic glycogen storage diseases.
Bhattacharya K
Translational pediatrics 2015; (4(3)):240-8 doi:10.3978/j.issn.2224-4336.2015.04.07.
PMID: 26835382 - 6
Sleep and quality of life of patients with glycogen storage disease on standard and modified uncooked cornstarch.
Rousseau-Nepton I, Huot C, Laforte D, et al.
Molecular genetics and metabolism 2018; (123(3)):326-330 doi:10.1016/j.ymgme.2017.09.003.
PMID: 29223626 - 7
Uncooked cornstarch for the prevention of hypoglycemic events.
Della Pepa G, Vetrani C, Lupoli R, et al.
Critical reviews in food science and nutrition 2022; (62(12)):3250-3263 doi:10.1080/10408398.2020.1864617.
PMID: 33455416 - 8
Fluorodeoxyglucose-positron emission tomography as a potential alternative tool for functional diagnosis of glycogen storage disease type I.
Sato T, Inokuchi M, Nakano S, et al.
Radiology case reports 2023; (18(1)):91-93 doi:10.1016/j.radcr.2022.09.084.
PMID: 36324837 - 9
A patient with glycogen storage disease type Ia combined with chronic hepatitis B infection: a case report.
Wang W, Yu R, Tan W, et al.
BMC medical genetics 2019; (20(1)):85 doi:10.1186/s12881-019-0816-9.
PMID: 31109299 - 10
Clinical and Genetic Profile of 35 Patients with Glycogen Storage Disease Type 1b: A Comparative Analysis Before and During SGLT2 Inhibitor Therapy.
Milosevic MD, Skakic A, Kecman B, et al.
Molecular diagnosis & therapy 2025; (29(5)):655-673 doi:10.1007/s40291-025-00795-5.
PMID: 40536628 - 11
Role of continuous glucose monitoring in the management of glycogen storage disorders.
Herbert M, Pendyal S, Rairikar M, et al.
Journal of inherited metabolic disease 2018; (41(6)):917-927 doi:10.1007/s10545-018-0200-5.
PMID: 29802555 - 12
Hypoglycaemic Unawareness in a Glycogen Storage Disorder Patient: A Case Report and Review of the Literature.
Alkundi A, Momoh R
Cureus 2025; (17(4)):e81805 doi:10.7759/cureus.81805.
PMID: 40330337 - 13
Hepatic Resection and Transplant in Glycogen Storage Diseases.
Singh N, El-Hinnawi A, Hill B, et al.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2022; (20(6)):609-612 doi:10.6002/ect.2019.0313.
PMID: 32039669 - 14
Genome editing using Staphylococcus aureus Cas9 in a canine model of glycogen storage disease Ia.
Arnson B, Kang HR, Brooks ED, et al.
Molecular therapy. Methods & clinical development 2023; (29()):108-119 doi:10.1016/j.omtm.2023.03.001.
PMID: 37021039 - 15
Development of Hepatocellular Carcinoma in Patients with Glycogen Storage Disease: a Single Center Retrospective Study.
Jang HJ, Yang HR, Ko JS, et al.
Journal of Korean medical science 2020; (35(1)):e5 doi:10.3346/jkms.2020.35.e5.
PMID: 31898434 - 16
Matched unrelated donor transplantation in glycogen storage disease type 1b patient corrects severe neutropenia and recurrent infections.
Mehyar LS, Abu-Arja R, Rangarajan HG, et al.
Bone marrow transplantation 2018; (53(8)):1076-1078 doi:10.1038/s41409-018-0147-z.
PMID: 29515247
This page provides educational information about dietary management and cornstarch therapy for GSD I. Always consult your metabolic specialist and dietitian before making any changes to your feeding schedule or treatment plan.
Get notified when new evidence is published on Glycogen storage disease due to glucose-6-phosphatase deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.